Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in non-atopic versus allergic severe asthma
NL-OMON42417Withdrawn
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of omalizumab in asthma (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Expression levels of FcεRI on basophils. Planned start Jan 2016; status: withdrawn.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON42417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42417.